Zum Hauptinhalt springen
Dekorationsartikel gehören nicht zum Leistungsumfang.
Drug Truths
Dispelling the Myths about Pharma R & D
Taschenbuch von John L Lamattina
Sprache: Englisch

37,00 €*

inkl. MwSt.

Versandkostenfrei per Post / DHL

Aktuell nicht verfügbar

Kategorien:
Beschreibung
An insider's perspective on the pharmaceutical industry

It's easy to hate Big Pharma. After all, they charge a lot of money for life-saving drugs. You could argue that Big Pharma's incentive to generate income is antithetical to the needs of society. But, if you set costs aside, no reasonable person could argue against the industry's accomplishments. The pharmaceutical industry has cured many infectious diseases and some cancers, delayed the onset of heart disease, enabled AIDS patients to live long and productive lives, controlled the progression of arthritis, and reduced pain.

Any thoughtful discussion on the pharmaceutical industry must be guided by the facts. Author John LaMattina, a thirty-year veteran and former president of Pfizer Global Research and Development, takes you through the realities and the myths surrounding the pharmaceutical industry, offering concrete illustrative examples. Rather than innuendo, he offers facts, answering your questions about the process and costs of pharmaceutical R&D in a compelling narrative focused on the discovery and development of new medicines.

Divided into four parts, this book dispels common misconceptions, helping you arrive at your own informed conclusions:
* Part One, A Matter of the Heart
* Part Two, The Role of Pharmaceutical R&D in Healthcare
* Part Three, The Profit Motive
* Part Four, The Future

With its emphasis on fact, John LaMattina's book is indispensable for anyone interested in understanding, advocating, or setting pharmaceutical policy, including general consumers, pharmaceutical executives, regulators, pharmaceutical researchers, and students.

"This is an important and timely book."
-Dr. Richard A. Lerner, President of the Scripps Research Institute

"Drug Truths is an authoritative, clear, and accessible exposition of the realities of drug discovery and development."
-Professor E.J. Corey, Nobel Laureate, Harvard University
An insider's perspective on the pharmaceutical industry

It's easy to hate Big Pharma. After all, they charge a lot of money for life-saving drugs. You could argue that Big Pharma's incentive to generate income is antithetical to the needs of society. But, if you set costs aside, no reasonable person could argue against the industry's accomplishments. The pharmaceutical industry has cured many infectious diseases and some cancers, delayed the onset of heart disease, enabled AIDS patients to live long and productive lives, controlled the progression of arthritis, and reduced pain.

Any thoughtful discussion on the pharmaceutical industry must be guided by the facts. Author John LaMattina, a thirty-year veteran and former president of Pfizer Global Research and Development, takes you through the realities and the myths surrounding the pharmaceutical industry, offering concrete illustrative examples. Rather than innuendo, he offers facts, answering your questions about the process and costs of pharmaceutical R&D in a compelling narrative focused on the discovery and development of new medicines.

Divided into four parts, this book dispels common misconceptions, helping you arrive at your own informed conclusions:
* Part One, A Matter of the Heart
* Part Two, The Role of Pharmaceutical R&D in Healthcare
* Part Three, The Profit Motive
* Part Four, The Future

With its emphasis on fact, John LaMattina's book is indispensable for anyone interested in understanding, advocating, or setting pharmaceutical policy, including general consumers, pharmaceutical executives, regulators, pharmaceutical researchers, and students.

"This is an important and timely book."
-Dr. Richard A. Lerner, President of the Scripps Research Institute

"Drug Truths is an authoritative, clear, and accessible exposition of the realities of drug discovery and development."
-Professor E.J. Corey, Nobel Laureate, Harvard University
Über den Autor
John L. LaMattina, PhD, retired as president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire.
Inhaltsverzeichnis

ACKNOWLEDGMENTS ix

INTRODUCTION xi

PART I A MATTER OF THE HEART 1

CHAPTER 1 CHOLESTEROL DRUGS ARE UNNECESSARY 3

CHAPTER 2 INDUSTRY IS MORE INTERESTED IN "ME-TOO" DRUGS THAN IN INNOVATION 13

CHAPTER 3 IT TAKES INDUSTRY TOO LONG TO DISCOVER NEW DRUGS 23

PART II THE ROLE OF PHARMACEUTICAL R&D IN HEALTH CARE 39

CHAPTER 4 DRUGS ARE DISCOVERED BY ACADEMIA 41

CHAPTER 5 NEW MEDICINES ADD COSTS BUT LITTLE BENEFIT 50

CHAPTER 6 BIG PHARMA HAS FAILED AND SHOULD LEARN FROM BIOTECH SUCCESS 59

PART III THE PROFIT MOTIVE 69

CHAPTER 7 THE INDUSTRY INVENTS DISEASES 71

CHAPTER 8 NEW DRUGS ARE LESS SAFE THAN TRADITIONAL MEDICINES 79

CHAPTER 9 INDUSTRY SPENDS MORE ON ADVERTISING THAN ON R&D 91

CHAPTER 10 INDUSTRY DOES NOT CARE ABOUT DISEASES OF THE DEVELOPING WORLD 100

PART IV THE FUTURE 109

CHAPTER 11 BIG PHARMA'S DAY HAS PASSED 111

CHAPTER 12 FINAL REFLECTIONS 122

REFERENCES 124

INDEX 133

Details
Erscheinungsjahr: 2008
Fachbereich: Populäre Darstellungen
Genre: Chemie
Rubrik: Naturwissenschaften & Technik
Medium: Taschenbuch
Inhalt: 152 S.
ISBN-13: 9780470393185
ISBN-10: 0470393181
Sprache: Englisch
Herstellernummer: 14539318000
Einband: Kartoniert / Broschiert
Autor: Lamattina, John L
Hersteller: Wiley
John Wiley & Sons
Maße: 234 x 156 x 9 mm
Von/Mit: John L Lamattina
Erscheinungsdatum: 01.11.2008
Gewicht: 0,248 kg
Artikel-ID: 101735577
Über den Autor
John L. LaMattina, PhD, retired as president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and support professionals in the United States, Europe, and Asia. Dr. LaMattina has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire.
Inhaltsverzeichnis

ACKNOWLEDGMENTS ix

INTRODUCTION xi

PART I A MATTER OF THE HEART 1

CHAPTER 1 CHOLESTEROL DRUGS ARE UNNECESSARY 3

CHAPTER 2 INDUSTRY IS MORE INTERESTED IN "ME-TOO" DRUGS THAN IN INNOVATION 13

CHAPTER 3 IT TAKES INDUSTRY TOO LONG TO DISCOVER NEW DRUGS 23

PART II THE ROLE OF PHARMACEUTICAL R&D IN HEALTH CARE 39

CHAPTER 4 DRUGS ARE DISCOVERED BY ACADEMIA 41

CHAPTER 5 NEW MEDICINES ADD COSTS BUT LITTLE BENEFIT 50

CHAPTER 6 BIG PHARMA HAS FAILED AND SHOULD LEARN FROM BIOTECH SUCCESS 59

PART III THE PROFIT MOTIVE 69

CHAPTER 7 THE INDUSTRY INVENTS DISEASES 71

CHAPTER 8 NEW DRUGS ARE LESS SAFE THAN TRADITIONAL MEDICINES 79

CHAPTER 9 INDUSTRY SPENDS MORE ON ADVERTISING THAN ON R&D 91

CHAPTER 10 INDUSTRY DOES NOT CARE ABOUT DISEASES OF THE DEVELOPING WORLD 100

PART IV THE FUTURE 109

CHAPTER 11 BIG PHARMA'S DAY HAS PASSED 111

CHAPTER 12 FINAL REFLECTIONS 122

REFERENCES 124

INDEX 133

Details
Erscheinungsjahr: 2008
Fachbereich: Populäre Darstellungen
Genre: Chemie
Rubrik: Naturwissenschaften & Technik
Medium: Taschenbuch
Inhalt: 152 S.
ISBN-13: 9780470393185
ISBN-10: 0470393181
Sprache: Englisch
Herstellernummer: 14539318000
Einband: Kartoniert / Broschiert
Autor: Lamattina, John L
Hersteller: Wiley
John Wiley & Sons
Maße: 234 x 156 x 9 mm
Von/Mit: John L Lamattina
Erscheinungsdatum: 01.11.2008
Gewicht: 0,248 kg
Artikel-ID: 101735577
Warnhinweis

Ähnliche Produkte

Ähnliche Produkte